Ligand Pharmaceuticals

Quarterly Financials

Values in thousands2026-03-312025-12-312025-09-302025-06-30
Revenue
$51,722
$59,666
$115,461
$47,627
Gross Profit
49,647
85,654
90,641
44,720
EBITDA
17,368
66,404
149,232
20,898
EBIT
56,780
141,137
12,376
Net Income
-13,345
44,784
117,273
4,847
Net Change In Cash
51,722
59,666
115,461
47,627
Free Cash Flow
48,463
45,835
13,075
15,583
Cash
115,077
174,927
139,376
67,669
Basic Shares
19,883
21,138
20,170
19,926

Annual Financials

Values in thousands2025-12-312024-12-312023-12-312022-12-31
Revenue
$268,087
$167,133
$131,314
$196,245
Gross Profit
261,499
156,059
96,265
143,418
EBITDA
192,735
40,794
100,837
81,204
EBIT
158,960
5,555
64,316
37,810
Net Income
124,453
-4,032
52,154
-33,361
Net Change In Cash
268,087
167,133
131,314
196,245
Free Cash Flow
48,907
77,407
-4,272
119,927
Cash
174,927
72,307
22,954
45,006
Basic Shares
20,294
18,290
17,757
16,868

Earnings Calls

QuarterEPS
2026-03-31
-$0.67
2025-12-31
$2.02
2025-09-30
$3.09
2025-06-30
$1.60